Isotope Product Laboratories, Battelle join forces

AuntMinnie.com staff writers
Apr 25, 2005

Calibration-source developer Isotope Product Laboratories (IPL) has signed a collaborative agreement with science and technology enterprise Battelle to develop a radiopharmaceutical-grade 68Ge/68Ga radionuclide generating system.

Battelle and Valencia, CA-based IPL said they would be engaging their respective research and development teams and technology portfolios to lay the foundation for extending IPL's existing 68Ge/68Ga generator system into a radiopharmaceutical-grade platform. Scientific development by Battelle staff will be performed at Pacific Northwest National Laboratory (PNNL) in Richland, WA. Battelle operates PNNL for the U.S. Department of Energy.

By AuntMinnie.com staff writers
April 26, 2005

Related Reading

DraxImage, Isotope Products ink distribution deal, March 22, 2004

Copyright © 2005 AuntMinnie.com

Latest in Molecular Imaging
Representative maximum-intensity projections of five patients (patients 3, 5, 7, 10, and 11) comparing Ga-68 NYM046 and F-18 FDG. Both tracers showed specific retention in bone and lymph node metastases (patients 10 and 11). Ga-68 NYM046 PET/CT outperformed F-18 FDG PET/CT in detecting primary tumors, lung metastases, and pleural metastases (patients 3, 5, 7, and 11). Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of the Journal of Nuclear Medicine.
New PET tracer shows promise in patients with kidney cancer
November 14, 2024
New! Imaging Life Issue 20 now available
Sponsored
New! Imaging Life Issue 20 now available
November 5, 2024
Hyperparathyroidism
FCH-PET emerging in patients with hyperparathyroidism
October 31, 2024
Heart Attack
Ask cardiac PET patients how much they exercise, study suggests
October 30, 2024
Related Stories
187x200 Am Logo
Companies
AuntMinnie.com
2005 04 25 15 10 14 706
Nuclear Medicine
More PET/CT lung masses seen with hardware-based fusion
2005 04 06 14 10 48 706
Molecular Imaging
Molecular imaging advances give hyperparathyroid patients more choices
New! Imaging Life Issue 20 now available
Sponsor Content
New! Imaging Life Issue 20 now available
More in Molecular Imaging
New PET tracer shows promise in patients with kidney cancer
By Will Morton
A new PET radiotracer could offer a viable strategy for detecting primary tumors, involved lymph nodes, and distant metastases in patients with clear cell renal cell carcinoma.
November 14, 2024
Representative maximum-intensity projections of five patients (patients 3, 5, 7, 10, and 11) comparing Ga-68 NYM046 and F-18 FDG. Both tracers showed specific retention in bone and lymph node metastases (patients 10 and 11). Ga-68 NYM046 PET/CT outperformed F-18 FDG PET/CT in detecting primary tumors, lung metastases, and pleural metastases (patients 3, 5, 7, and 11). Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of the Journal of Nuclear Medicine.
SPECT/CT predicts treatment response in Pluvicto patients
By Will Morton
SPECT/CT scans taken just four hours after patients begin Lu-177 PSMA-617 treatment can help assess treatment responses.
November 1, 2024
Pluvicto Spect Ct Response Thumbnail
FCH-PET emerging in patients with hyperparathyroidism
By Will Morton
F-18 fluorocholine (FCH) PET/CT appears to be an effective first-line imaging method in patients with primary hyperparathyroidism.
October 31, 2024
Hyperparathyroidism
Ask cardiac PET patients how much they exercise, study suggests
By Will Morton
Exercise activity is an independent predictor of events such as heart attacks in patients undergoing stress PET myocardial perfusion imaging.
October 30, 2024
Heart Attack
Intraarterial PRRT safe in patients with meningioma
By Will Morton
Intraarterial peptide receptor radionuclide therapy (PRRT) is a safe and effective alternative to intravenous PRRT in patients with advanced meningioma.
October 28, 2024
2024 10 28 Meningioma Thumbnail
PSMA-PET provides long-term benefits
By Will Morton
Prostate-specific membrane antigen (PSMA) PET imaging could improve the length and quality of life for patients with recurrent prostate cancer.
October 24, 2024
Prostate Imaging2
New PET tracer improves detection of insulinomas
By Will Morton
A new PET/CT radiotracer that detects insulinomas could eliminate the need for other diagnostic procedures in a vast majority of patients.
October 21, 2024
Glp 1 R Pet 67169a712e569 Thumbnail
Tc-99m shortage expected into November
By Will Morton
The delayed restart of a nuclear research reactor in the Netherlands is expected to cause supply shortages of technetium-99m (Tc-99m) into November.
October 18, 2024
Isotopes
FAPI-PET shows value in staging lung cancer patients
By Will Morton
Fibroblast activation protein inhibitor (FAPI) PET/CT shows excellent diagnostic accuracy for detecting lymph node metastases in lung cancer patients
October 17, 2024
Lung Cancer
New guidelines cover theranostics for brain tumors
By Will Morton
The use of somatostatin receptor PET imaging and therapy in meningiomas is on the rise.
October 14, 2024
Brain
NNSA's Mo-99 program: A bumpy ride
By Will Morton
Last year was a bumpy ride for a U.S. initiative to secure domestic supplies of molybdenum-99 (Mo-99).
October 10, 2024
Mo 99
FES-PET improves management of breast cancer patients
By Will Morton
PET/CT imaging with F-18 fluroestradiol (FES) can play a significant role in helping clinicians make treatment decisions in patients with recurrent or metastatic breast cancer
October 7, 2024
2024 10 07 Fes Pet Thumbnail
Page 1 of 598
Next Page